Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras [PDF]
Memorias do Instituto Oswaldo Cruz, 2009 Between 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras ...
Josep M Escribà +9 more
doaj +4 more sources
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA). [PDF]
PLoS Neglected Tropical DiseasesIntroductionThe currently recommended 8-week daily benznidazole regimen for Chagas disease is poorly tolerated. While shorter benznidazole monotherapy and combination regimens have been explored, the pharmacokinetic/pharmacodynamic (PK/PD) relationship ...
Frauke Assmus +9 more
doaj +2 more sources
Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. [PDF]
PLoS Neglected Tropical Diseases, 2016 BackgroundChronic infection by Trypanosoma cruzi could cause heart conduction disturbances. We sought to analyze electrocardiographic abnormalities among children with chronic T.
Lisandro D Colantonio +3 more
doaj +3 more sources
Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. [PDF]
PLoS Neglected Tropical DiseasesAnti-trypanosomal therapy is generally recommended for individuals under age 50 with the indeterminate form of Chagas disease to prevent disease progression. However, benznidazole and nifurtimox are associated with adverse drug reactions.
Katherine Reifler +13 more
doaj +2 more sources
Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease. [PDF]
PLoS Neglected Tropical DiseasesBackgroundThere is an urgent need for improved treatments for Chagas disease, a neglected tropical infection caused by the protozoan parasite Trypanosoma cruzi.
Frauke Assmus +12 more
doaj +2 more sources
Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults [PDF]
, 2014 Introduction:Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology ...
Altcheh, Jaime Marcelo +9 more
core +34 more sources
Microbiology Spectrum, 2022 Dermatitis is the most common adverse event during treatment with benznidazole in chronic Chagas disease and is probably mediated by T cells. A set of molecules representative of the different type IV hypersensitivity reactions was evaluated in the ...
Melisa D. Castro Eiro +17 more
doaj +1 more source
Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi. [PDF]
PLoS Neglected Tropical Diseases, 2018 BACKGROUND:Drugs currently used for the treatment of Chagas' disease, nifurtimox and benznidazole, have a limited effectiveness and toxic side effects.
Vanesa Puente +4 more
doaj +1 more source
Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model
Pharmaceuticals, 2023 Chagas disease (ChD), caused by Trypanosoma cruzi, is the most serious parasitosis in the western hemisphere. Benznidazole and nifurtimox, the only two trypanocidal drugs, are expensive, difficult to obtain, and have severe side effects. Nitazoxanide has
Minerva Arce-Fonseca +5 more
doaj +1 more source
Synthesis, In Silico Studies, Antiprotozoal and Cytotoxic Activities of Quinoline‐Biphenyl Hybrids [PDF]
, 2020 This is the pre-peer reviewed version of the following article: Synthesis, In Silico Studies, Antiprotozoal and Cytotoxic Activities of Quinoline‐Biphenyl Hybrids, which has been published in final form at https://doi.org/10.1002/slct.201903835.
Carda, Miguel +6 more
core +1 more source